Αρχική World News Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of... World News Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC Από Ogkologos - 9 Σεπτεμβρίου, 2025 811 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ESMO Calls on the European Commission to Fund Cancer Research and... 23 Σεπτεμβρίου, 2026 Learning to Live With Cancer: A Survivor’s Story 30 Νοεμβρίου, 2023 Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides... 9 Φεβρουαρίου, 2021 Significant Interaction Between a Chemotherapy Benefit and Menopausal Status Found in... 7 Δεκεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All... FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of... Coping With War and Cancer: How to Take Care of Your... The UK Government’s spending review: Time to invest in the future...